No profile data available.
Takeda Pharmaceutical Company Limited (TAK) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Chuo, Japan, with about 47,029 full-time employees.
It reported revenue of 4.51 trillion JPY for fiscal year 2026, down 1.7% from fiscal year 2025, and net income of -152.39 billion JPY. In Q1 2027 (the quarter ended June 30, 2026) revenue was 1.22 trillion JPY, up 10.2% from a year before. United States was its largest region in fiscal year 2026, with 48% of revenue. Its market capitalization was $59.83 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2026; market data as of October 9, 2026.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Takeda Pharmaceutical reported 4.51 trillion JPY in revenue for fiscal year 2026, down 1.7% from 4.58 trillion JPY in fiscal year 2025. In Q1 2027 revenue was 1.22 trillion JPY.
United States: 48% of revenue by region in fiscal year 2026, followed by Europe and Canada (25%).
$59.83 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Pfizer Inc. (PFE), Sanofi (SNY), GSK plc (GSK), Teva Pharmaceutical Industries Limited (TEVA).